---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-145634"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:42:09.180993+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atea Q1 net loss $42.1M; bemnifosbuvir misses primary endpoint but shows 71% hospitalization reduction

## Summary
- Net loss of $42.1M ($0.51 per diluted share) vs net income of $30.7M in Q1 2021; revenue $0 vs $65.985M due to Roche termination.
- Cash and equivalents $705.5M at March 31, 2022, down from $764.4M at Dec 31, 2021; $25M paid to Merck for ruzasvir license.
- Bemnifosbuvir MORNINGSKY trial: primary endpoint (time to symptom alleviation) not met; 71% reduction in hospitalization (2.9% vs 10%, p=0.047, exploratory).
- Phase 2 hospitalized COVID-19 study: 7.5% PRI on bemnifosbuvir vs 10% placebo; 0 deaths vs 3 deaths in placebo.
- Initiated Phase 2 DEFEND-2 and human challenge trial for AT-752 in dengue; results expected 4Q22 and late 2022.

## SEC filing metadata
- accession: 0001193125-22-145634
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312522145634/0001193125-22-145634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312522145634/d259165d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-145634
- JSON: https://secwatch.observer/filing/0001193125-22-145634.json
- Plain text: https://secwatch.observer/filing/0001193125-22-145634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.